Molina Healthcare earnings release, October 21, 2026

Molina Healthcare, Inc. (MOH) · Form 8-K, Item 2.02 · Filed · SEC filing

News Release

Investor Contact:

Jeffrey Geyer,

Jeffrey.Geyer@molinahealthcare.com, 305-317-3012

Media Contact:

Caroline Zubieta,

Caroline.Zubieta@molinahealthcare.com, 562-542-1845

Molina Healthcare Reports Third Quarter 2026 Financial Results

Reaffirms Full Year 2026 Earnings Guidance

Long Beach, Calif., October 21, 2026 – Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported third quarter 2026 GAAP income per diluted share of $0.73 and adjusted income per diluted share of $0.89. Financial results are summarized below:

Quarter Highlights

• As of September 30, 2026, the Company served approximately 4.9 million members.

• Premium revenue was approximately $10.5 billion for the third quarter of 2026.

• Third quarter 2026 GAAP income per diluted share was $0.73 and adjusted income per diluted share was $0.89.

• The Company reaffirmed its full year 2026 guidance of expected premium revenue of approximately $42 billion and adjusted earnings of at least $5.25 per diluted share.

“We are pleased with our third quarter results in this challenging environment and reaffirm our full year guidance,” said Joseph Zubretsky, President and Chief Executive Officer. “With the apparent plateauing of medical cost trend, which remains at elevated levels, and the strength of recent rate updates for 2027, we believe we are likely observing the beginning of the turn in Medicaid margins.”

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 2

October 21, 2026

Premium Revenue

Premium revenue was approximately $10.5 billion for the third quarter of 2026, a decrease of 4% year over year. The lower premium revenue reflects the impact of lower membership in Medicaid and Marketplace, partially offset by rate updates.

Net Income

GAAP net income for the third quarter of 2026 was $38 million, or $0.73 per diluted share, a decrease of 52% year over year. Adjusted net income for the third quarter of 2026 was $46 million, or $0.89 per diluted share, a decrease of 53% year over year. The decrease is attributed mainly to a higher consolidated MCR.

Medical Care Ratio (MCR)

• The consolidated MCR for the third quarter of 2026 was 92.9%.

• The Medicaid MCR for the third quarter of 2026 was 93.0% and in line with the Company’s expectations, reflecting rate updates and stable medical cost trend.

• The Medicare MCR for the third quarter of 2026 was 93.0% and in line with the Company’s expectations, reflecting stable medical cost trend.

• The Marketplace MCR for the third quarter of 2026 was 92.5% and in line with normal seasonality and the Company’s expectations.

General and Administrative Expense Ratio

The G&A ratio and the adjusted G&A ratio for the third quarter of 2026 were 6.4% and 6.3%, respectively, reflecting continued operating discipline.

Balance Sheet

Cash and investments at the parent company were approximately $608 million as of September 30, 2026, compared to $223 million as of December 31, 2025.

Days in claims payable at September 30, 2026, was 44, consistent with June 30, 2026.

Cash Flow

Operating cash flow for the nine months ended September 30, 2026, was $629 million, compared to an outflow of $237 million for the nine months ended September 30, 2025. The increase compared to the prior year was driven mainly by lower government receivable and payable settlements in 2026.

2026 Guidance

Premium revenue guidance for the full year is unchanged at approximately $42 billion.

The Company expects its full year 2026 GAAP earnings to be at least $2.38 per diluted share and reaffirmed its full year 2026 adjusted earnings of at least $5.25 per diluted share. Guidance metrics across all segments are also reaffirmed. Full year earnings guidance includes a loss of $1.50 per share due to the implementation of the new Florida Medicaid contract in the fourth quarter of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD product, which the Company previously announced it will exit for 2027.

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 3

October 21, 2026

Conference Call

Management will host a conference call and webcast to discuss Molina Healthcare’s third quarter ended September 30, 2026 results, at 8:00 a.m. Eastern Time on Thursday, October 22, 2026. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 6534841. A telephonic replay of the conference call will be available through Thursday, October 29, 2026, by dialing (855) 669-9658 and entering confirmation number 4361465.

A live audio broadcast of this conference call will be available on Molina Healthcare’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com.

Financial statements

Income Statement

Three months ended (in millions)

Three months ended – September 30, – 2026Three months ended – September 30, – 2025Nine months ended – September 30, – 2026Nine months ended – September 30, – 2025
Premium Revenue10,45710,84130,87332,337
Total Revenue11,08211,47732,75234,051
GAAP:Net Income3879112632
GAAP:EPS – Diluted0.731.512.1911.79
GAAP:Medical Care Ratio (MCR)92.992.692.190.8
GAAP:G&A Ratio6.46.46.86.5
GAAP:Pre-tax Margin0.50.80.52.4
Adjusted:Net Income4697243724
Adjusted:EPS – Diluted0.891.844.7413.49
Adjusted:G&A Ratio6.36.36.66.4
Adjusted:Pre-tax Margin0.611.12.7

Income Statement

Three Months Ended — UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (in millions)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Revenue:Premium revenue10,45710,84130,87332,337
Revenue:Premium tax revenue5005061,5091,325
Revenue:Investment income102108301322
Revenue:Other revenue23226967
Revenue:Total revenue11,08211,47732,75234,051
Operating expenses:Medical care costs9,71910,04428,42929,352
Operating expenses:General and administrative expenses7107292,2132,214
Operating expenses:Premium tax expenses5005061,5091,325
Operating expenses:Depreciation and amortization3845117151
Operating expenses:Impairment93
Operating expenses:Other9165766
Operating expenses:Total operating expenses10,97611,34032,41833,108
Operating expenses:Operating income106137334943
Operating expenses:Interest expense5349161140
Operating expenses:Income before income tax expense5388173803
Operating expenses:Income tax expense15961171
Operating expenses:Net income3879112632
Operating expenses:Net income per share – Diluted0.731.512.1911.79
Operating expenses:Diluted weighted average shares outstanding51.552.551.353.6

Balance Sheet

September 30, — CONSOLIDATED BALANCE SHEETS (in millions)

September 30, – 2026 – Unaudited – ASSETSDecember 31, – 2025 – ASSETS
Current assets:Cash and cash equivalents4,4794,248
Current assets:Investments4,1004,008
Current assets:Receivables3,3593,533
Current assets:Prepaid expenses and other current assets576655
Current assets:Total current assets12,51412,444
Current assets:Property, equipment, and capitalized software, net324301
Current assets:Goodwill and intangible assets, net2,0732,195
Current assets:Restricted investments345299
Current assets:Deferred income taxes, net267178
Current assets:Other assets129147
Current assets:Total assets15,65215,564
Current liabilities:Medical claims and benefits payable4,9884,887
Current liabilities:Amounts due government agencies1,1411,326
Current liabilities:Accounts payable, accrued liabilities and other1,1831,093
Current liabilities:Deferred revenue8266
Current liabilities:Total current liabilities7,3947,372
Current liabilities:Long-term debt3,7713,766
Current liabilities:Finance lease liabilities179184
Current liabilities:Other long-term liabilities153173
Current liabilities:Total liabilities11,49711,495
Stockholders’ equity:Additional paid-in capital536452
Stockholders’ equity:Accumulated other comprehensive (loss) income-9515
Stockholders’ equity:Retained earnings3,7143,602
Stockholders’ equity:Total stockholders’ equity4,1554,069
Stockholders’ equity:Total liabilities and stockholders’ equity15,65215,564

Cash Flow

Nine Months Ended — UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions)

Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Operating activities:Net income112632
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Depreciation and amortization117151
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Deferred income taxes-5437
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Share-based compensation8527
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Impairment93
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Other, net-21-2
Changes in operating assets and liabilities:Receivables174-118
Changes in operating assets and liabilities:Prepaid expenses and other current assets11-25
Changes in operating assets and liabilities:Medical claims and benefits payable101-157
Changes in operating assets and liabilities:Amounts due government agencies-185-467
Changes in operating assets and liabilities:Accounts payable, accrued liabilities and other88-195
Changes in operating assets and liabilities:Deferred revenue16-44
Changes in operating assets and liabilities:Income taxes92-76
Changes in operating assets and liabilities:Net cash provided by (used in) operating activities629-237
Investing activities:Purchases of investments-1,245-607
Investing activities:Proceeds from sales and maturities of investments1,0201,017
Investing activities:Purchases of property, equipment, and capitalized software-94-102
Investing activities:Net cash paid in business combinations-245
Investing activities:Other, net-919
Full release

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995... (truncated)th,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding the Company’s 2026 guidance and long-term performance outlook, trends with respect to rates, pretax margins, utilization, and medical costs, including the timing thereof and the anticipated impact on the Company’s business, and our management’s plans and objectives for future operations and business strategy.

Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025, which is on file with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Reports on Form 10-Q for the period ended March 31, 2026 and June 30, 2026 filed with the SEC and Quarterly Report on Form 10-Q for the period ended September 30, 2026, to be filed with the SEC.

These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of October 21, 2026, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations.

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 4

October 21, 2026

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.